ASH 2021 | Investigating TG-1701, a novel BTKi, in CLL and NHL
Constantine Tam
• 12 Dec 2021
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, presents findings from a Phase I trial (NCT03671590) of TG-1701, an irreversible Bruton’s tyrosine kinase (BTK) inhibitor, in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Patients received either TG-1701 as a monotherapy or with ublituximab and umbralisib (U2). Both arms reported encouraging efficacy and safety profiles, and demonstrates the potential of BTK inhibitors with U2. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
